µ²ºc¦¡ |
|
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Timolol¡G¬O¤A«¬-1©M¤A«¬-2 («D¿ï¾Ü©Êªº)ªºµÇ¤W¸¢¯À±µ¨üÅéªýÂ_¾¯¡A¤£¨ã¦³©úÅ㪺¤º¥Í©ÊÀÀ¥æ·P¯«¸g¾¯¡Bª½±µ¤ß¦Ù§í¨î¾¯©Î§½³¡³Â¾K¾¯¡]½¤Ã©w¡^µ¥ÃþÃÄ«~ªº¬¡©Ê¡CTimololÂǥѴî¤ÖÅÖ¤ò¤W¥Ö²ÓM§Î¦¨©Ð¤ôªº§@¥Î¨Ó°§C²´¤ºÀ£¡C¥Ø«e¨Ã¤£²M·¡timolol°§C²´¤ºÀ£ªº¯u¥¿§@¥Î¾÷Âà¡A¦ý¥i¯à¬O¨Ï¦]¤º¥Í©Ê¤A«¬µÇ¤W¸¢¯À¨ë¿E§@¥Î¦Ó¼W¥[¦X¦¨cAMPªº±¡§Î¨ü¨ì§í¨î¡CTimolol¨Ã¤£·|©úÅã¼vÅT¦å²G-©Ð¤ô«Ì»Ù»P¦å¼ß³J¥Õ¶¡ªºº¯³z©Ê¡C
|
¾AÀ³¯g |
|
°ª²´À£¯g¡A¼s¨¤©Ê«C¥ú²´¡C
|
¥Îªk¥Î¶q |
|
±`¥Î°_©l¾¯¶q¬°0.25% TIMOPTOL-XEºw©ó±w²´¤@ºw¡A¤@¤é¤@¦¸¡AYÁ{§É¤ÏÀ³¤£¨Î®É¡A¥i§ï¥H0.5% TIMOPTOL-XEºw©ó±w²´¤@ºw¡A¤@¤é¤@¦¸¡C¨Ï¥Î«e±N²~¤l¤ÏÂஶ·n¤@¦¸¡A¦ýµL»Ý®¶·n¶W¹L¤@¦¸¡C ¥²n®É¡ATIMOPTOL-XE¥i¨Ö¥Î¨ä¥LÃÄ«~¥H°§C²´¤ºÀ£¡A¦ý¤£«Øij¦P®É¨Ï¥Î¨âºØ¤A«¬µÇ¤W¸¢¯ÀªýÂ_¾¯ªvÀø(¨£ª`·N¨Æ¶µÄæ)¡CY©M¨ä¥L²´¥Î»s¾¯¨Ö¥Î®É¡A»Ý¥ý§ë»P¨ä¥L²´¥Î»s¾¯¡A¦Ü¤Ö¶¡¹j¤Q¤ÀÄÁ¥H¤W¡A¦A§ë»P¥»«~¡C
|
ÃİʤO¾Ç |
|
1.µ¹¤©TIMOPTOL-XE¡A¦b2-4¤p®É¤º²£¥Í³Ì¤jªº°²´À£®ÄªG¡A0.25%©M0.5% TIMOPTOL-XE§¡¯àºû«ù24¤p®É©úÅ㪺°²´À£§@¥Î¡C 2.Timolol maleateªº°_©l§@¥Î§Ö³t¡A¬ù¦b§½³¡µ¹ÃÄ«á20¤ÀÄÁ²£¥Í§@¥Î¡C
|
°Æ§@¥Î |
|
±`¨£ªºÃÄ«~¬ÛÃö°Æ§@¥Î¬°µ¹ÃÄ«á«ùÄò30¬í¦Ü5¤ÀÄÁªº¼È®É©Êµø¤O¼Ò½k(6%)¡C
|
¥æ¤¬§@¥Î |
|
Clonidine May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal.
Epinephrine Initial hypertensive episode followed by bradycardia may occur.
Ergot derivatives Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur.
Insulin Prolonged hypoglycemia with masking of symptoms may occur.
NSAIDs Some agents may impair antihypertensive effect.
Prazosin Orthostatic hypotension may be increased.
Theophyllines Elimination of theophylline may be reduced. Effects of both drugs may be reduced.
Verapamil Effects of both drugs may be increased.
|
¸T§Ò |
|
1.¹ï©ó±w¦³¤ÏÀ³©Ê®ð¹D¯e¯f¡B®ð³Ý©Î¦³®ð³Ý¯f¥v©ÎÄY«ªººC©Êªý¶ë©ÊªÍ³¡¯e±w¯f¯gªÌ¡CƒÜ 2.Äu©Ê¤ß·i¹LºC¡FÄu©Ð¶Ç¾Éªýº¢¡F¤G«×©Î¤T«×©Ð«Ç¶Ç¾Éªýº¢¡F©úÅã¤ß°IºÜ¡F¤ß¦]©Ê¥ð§J¡CƒÜ 3.¹ï¥»«~¦¨¤À¹L±ÓªÌ
|
µ¹¥I³W©w |
|
14.1.°ª²´À£¤Î«C¥ú²´²´¥Î»s¾¯(101/12/1¡B102/8/1¡B104/4/1¡B106/2/1¡B110/5/1) ¥»ÃþÃĪ«Àøµ{¾¯¶q¦p¤U¡G(106/2/1) 1.¦h¦¸¨Ï¥Î¥]¸Ë(³W®æ¶q¡Ù2.5mL): (1)³æ²´¨C4¶g³B¤è¬°1²~¡AÂù²´±o¨C2¶g©Î3¶g³B¤è1²~¡C(101/12/1¡B102/8/1¡B104/4/1) 2.³æ¦¸¨Ï¥Î¥]¸Ë(¤£§t¨¾»G¾¯)¡A³æ²´©ÎÂù²´¨C4¶g³B¤è¤ä¼Æ¦p¤U(106/2/1)¡G (1)¨C¤é¨Ï¥Î1¦¸ªÌ¡A30¤ä(§t)¥H¤U¡C (2)¨C¤é¨Ï¥Î2¦¸ªÌ¡A60¤ä(§t)¥H¤U¡C (3)¨C¤é¨Ï¥Î3¦¸ªÌ¡A90(§t)¤ä¥H¤U¡C (4)¨C¤é¨Ï¥Î4¦¸ªÌ¡A120(§t)¤ä¥H¤U¡C 3.ªvÀø®É¡A¤£±o¨Ö¥Î¨ä¥L¦PÃþÃÄ«~¡C
14.1.1.³æ¤è»s¾¯(90/10/1¡B101/12/1¡B104/4/1¡B106/2/1)¡G 1.£]-¥æ·P¯«¸gªýÂ_¾¯(£]-blockers ) 2.ºÒ»ÄÓþ?§í¨î¾¯(Carbonic anhydrase inhibitor) : ¹ï£]-blockers¦³¸T§Ò¡B¤£¾A©Î¨Ï¥Î®ÄªG¤£¨Î¤§¯f±w¨Ï¥Î¡C 3.«e¦C¸¢¯Àl¥Íª«Ãþ¡G (Prostaglandin analogues)¡G(93/2/1¡B101/12/1) (1)¹ï£]-blockers¨Ï¥Î®ÄªG¤£¨Î©Î¤£¾A¥Î¤§¯f±w¨Ï¥Î¡C©y¥ý¥H³æ¿W¨Ï¥Î¬°ì«h¡C (2)Àø®Ä¤´¤£¨¬®É¡A±o¨Ö¥Î¨ä¥L°²´À£¥ÎÃÄ(§t½Æ¤è»s¾¯)¡C
|
ª`·N¨Æ¶µ |
|
©M¨ä¥L²´¥Î»s¾¯¤@¼Ë¡A¥»«~¥i¯à¦³¥þ¨©Ê§l¦¬¡C¤A«¬µÇ¤W¸¢¯ÀªýÂ_¾¯§½³¡µ¹ÃÄ¥ç¥i¯àµo¥Í©M¥þ¨©Êµ¹ÃĤ@¼Ëªº¤£¨}¤ÏÀ³¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
»Ý©ó25¢XC¥H¤UÁ×¥úÀx¦s¡AÁקK§Ná
|